Microsatellite Instability Testing The latest news on microsatellite instability testing. Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Sep 19, 2021 MD Anderson Researchers Explore Neoadjuvant Keytruda in MSI-high Solid Tumors Sep 18, 2021 Gritstone Advances Personalized, Off-the-Shelf Cancer Vaccine Studies in Molecularly Defined Groups Premium Aug 26, 2021 Merck Nets Two Keytruda Approvals in Japan for TNBC, Colon Cancer Aug 5, 2021 Promega, Henlius to Develop Microsatellite Instability CDx for Cancer Drug Jul 22, 2021 FDA Grants Full Approval to Merck, Eisai's Keytruda, Lenvima Combo in Endometrial Cancer Jul 22, 2021 Inflammation Signature May Predict Checkpoint Inhibitor Response in Gastroesophageal Cancer, Study Finds Premium Jul 7, 2021 Treos Bio, Roche Partner on Colorectal Cancer Combination Trial Jun 29, 2021 BMS' Opdivo, Yervoy Combo Approved for dMMR, MSI-High Colorectal Cancer in Europe Jun 14, 2021 UK's NICE Recommends Approval of Opdivo, Yervoy for MSI-High, MMR-Deficient Colorectal Cancer May 14, 2021 NICE Recommends Keytruda for Metastatic MSI-High, Mismatch Repair-Deficient Colorectal Cancer Apr 29, 2021 TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis Apr 26, 2021 Chinese Regulators Accept Henlius' Serplulimab New Drug Application Apr 23, 2021 European Commission Approves GSK's Dostarlimab in Endometrial Cancer Apr 14, 2021 Tecentriq Response Analysis in MyPathway Study Bolsters Case for Higher TMB Cutoff Premium Mar 25, 2021 Oncologists Look to FDA as New Publications Poke Holes in TMB-High Keytruda Approval Premium Feb 26, 2021 CHMP Recommends Approval of GSK's Dostarlimab in Endometrial Cancer Jan 26, 2021 Merck Nabs EU Keytruda Approval for MSI-High, Mismatch Repair Deficient Colorectal Cancer Jan 7, 2021 MSK Researchers Chip Away at TMB Unknowns, Clarify Role in Predicting Immunotherapy Benefit Premium Dec 11, 2020 EMA Committee Recommends Approval of Keytruda in MSI-H Colorectal Cancer Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
